Rallybio Corporation (RLYB) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Analysis Summary
Trailing-twelve-month margins: gross margin -11.1%, operating margin -36.7%, net margin 70.5%.
At the current price of $17.09, RLYB trades at a P/E of 2.14 and an ROE of 68.56%. Market capitalisation stands at $91M.
Balance sheet quality for RLYB: current ratio of 14.5, net cash position of $54.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $17.09 |
| Market Cap | $91M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 2.14 |
| Price / Book | 1.02 |
| EV / EBITDA | -0.11 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 68.56% |
| Return on Invested Capital | -24.40% |
| Return on Assets | 46.45% |
| Gross Margin | -1107.59% |
| Operating Margin | -3672.29% |
| Net Margin | 7051.24% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 27.26 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -2.86 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| RLYB | Rallybio Corporation | $91M | 2.14 | 1.02 | 68.6% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | +1.91% |
| 3 months | +7.01% |
| Year-to-date | +211.29% |
| 1 year | +275.60% |
| 3 years | -55.03% |
| 5 years | -83.30% |
52-Week Range
| 52-week High | $17.57 |
| 52-week Low | $3.67 |
| Avg Volume (90d) | 44K |
Related companies: BOLD · CVKD · IBIO · INTS · ITRM · KLTO · QTTB
Explore sector: Healthcare · Biotechnology
More sections of RLYB: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks